Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB-110 SAD and MAD Study in Healthy and Hypertensive Participants
NCT07916961Phase 1Not yet recruiting
- Sponsor
- Antlia Bioscience, Inc.
- Start
- Nov 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AB-110 in hypertension (HTN) (4 arms), sponsored by Antlia Bioscience, Inc. Primary endpoints: Incidence of Adverse Events and Serious Adverse Events at Day 36 and Incidence of injection site reactions at Day 36. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
AB-110
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT07916961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07916961.